A proof-of-concept rat toxicity study highlights the potential utility and challenges of virtual control groups
Article Sidebar
Main Article Content
Abstract
The virtual control group (VCG) concept provides a potential opportunity to reduce animal use in drug development by replacing concurrent control groups (CCGs) in nonclinical toxicity studies. This work investigated the feasibility and reliability of using VCGs in place of CCGs. A historical control database (HCD), constructed from Genentech Inc. rat toxicity study data, was reviewed to understand trends and sources of variability in control animals over time, and to identify data curation requirements for assembling VCGs, e.g. alignment of units of measurement. Several endpoints were investigated and stratified against different study design parameters. Sex, route of administration, fasting status, and body weight at study initiation were among the parameters that were indicated as key matching criteria. With a high-level understanding of potential sources of variability, a retrospective proof-of-concept (POC) study was designed, evaluating a historical rat pilot toxicity study for test article-related changes. A masked interpretation of the study was conducted using its CCG, and two unique VCGs that were constructed from individual animal data pulled from our HCD. While the results of the microscopic pathology assessment and most endpoints were similar across the different control groups, the POC revealed the risk of using VCGs to interpret subtle test article-related changes in clinical pathology parameters. Within the context of our POC, it appears the use of a VCG is not completely equivalent to the CCG especially with clinical pathology parameters. Additional work is needed to understand the potential utility, and thus, viability of VCGs in other contexts.
Plain language summary
This study explored the use of virtual control groups (VCGs) as a potential method to reduce the number of living control animals in drug development. The process involves replacing concurrent control groups with historical animal data in nonclinical toxicity studies. Several parameters were identified as crucial factors that must be aligned before the construction of VCGs. The VCG concept was tested using a historical rat toxicity study, comparing results against the conventional control group as well as two unique VCGs. Although results were similar in most cases, potential risks in interpreting subtle changes in clinical pathology parameters were identified. Further work is needed to fully elucidate VCGs’ potential, and whether it is a viable alternative to current methods. The significance of this work lies in the possibility of reducing the number of animals used in testing, in support of the 3Rs (replace, reduce, and refine).
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles are distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited (CC-BY). Copyright on any article in ALTEX is retained by the author(s).
Ameri, M., Schnaars, H. A., Sibley, J. R. et al. (2011). Stability of hematologic analytes in monkey, rabbit, rat, and mouse blood stored at 4°C in EDTA using the ADVIA 120 hematology analyzer. Vet Clin Pathol 40, 188-193. doi:10.1111/j.1939-165X.2011.00304.x
Aulbach, A., Provencher, A. and Tripathi, N. (2017). Influence of study design variables on clinical pathology data. Toxicol Pathol 45, 288-295. doi:10.1177/0192623316677066
Aulbach, A. D., Schultze, E., Tripathi, N. K. et al. (2015). Factors affecting urine reagent strip blood results in dogs and nonhuman primates and interpretation of urinalysis in preclinical toxicology studies: A multi-institution contract research organization and biopharmaceutical company perspective. Vet Clin Pathol 44, 229-233. doi:10.1111/vcp.12245
Bonapersona, V., Hoijtink, H., Consortium, R. et al. (2021). Increasing the statistical power of animal experiments with historical control data. Nat Neurosci 24, 470-477. doi:10.1038/s41593-020-00792-3
Dhabhar, F. S., Miller, A. H., Stein, M. et al. (1994). Diurnal and acute stress-induced changes in distribution of peripheral blood leukocyte subpopulations. Brain Behav Immun 8, 66-79. doi:10.1006/brbi.1994.1006
Drevon-Gaillot, E., Perron-Lepage, M. F., Clement, C. et al. (2006). A review of background findings in cynomolgus monkeys (Macaca fascicularis) from three different geographical origins. Exp Toxicol Pathol 58, 77-88. doi:10.1016/j.etp.2006.07.003
Everds, N. E. (2017). Deciphering sources of variability in clinical pathology-it's not just about the numbers. Toxicol Pathol 45, 275-280. doi:10.1177/0192623316680783
Golden, E., Allen, D., Amberg, A. et al. (2023). Toward implementing virtual control groups in nonclinical safety studies. ALTEX, 41, 282-301. doi:10.14573/altex.2310041
Goyal, V. and Bandari, M. (2023). Rodents in drug discovery. In: Rodents and their role in ecology, medicine and agriculture. IntechOpen doi:10.5772/intechopen.1001323.
Grevot, A., Boisclair, J., Guffroy, M. et al. (2023). Toxicologic pathology forum opinion piece: Use of virtual control groups in nonclinical toxicity studies: The anatomic pathology perspective. Toxicol Pathol 51, 390-396. doi:10.1177/01926233231224805
Gunn-Christie, R. G., Flatland, B., Friedrichs, K. R. et al. (2012). Asvcp quality assurance guidelines: Control of preanalytical, analytical, and postanalytical factors for urinalysis, cytology, and clinical chemistry in veterinary laboratories. Vet Clin Pathol 41, 18-26. doi:10.1111/j.1939-165X.2012.00412.x
Gurjanov, A., Kreuchwig, A., Steger-Hartmann, T. et al. (2023). Hurdles and signposts on the road to virtual control groups-a case study illustrating the influence of anesthesia protocols on electrolyte levels in rats. Front Pharmacol 14, 1142534. doi:10.3389/fphar.2023.1142534
Gurjanov, A., Vieira-Vieira, C., Vienenkoetter, J. et al. (2024). Replacing concurrent controls with virtual control groups in rat toxicity studies. Regul Toxicol Pharmacol 148, 105592. doi:10.1016/j.yrtph.2024.105592
Hooijberg, E., Leidinger, E. and Freeman, K. P. (2012). An error management system in a veterinary clinical laboratory. J Vet Diagn Invest 24, 458-468. doi:10.1177/1040638712441782
Kale, V. P., Joshi, G. S., Gohil, P. B. et al. (2009). Effect of fasting duration on clinical pathology results in wistar rats. Vet Clin Pathol 38, 361-366. doi:10.1111/j.1939-165X.2009.00143.x
Kozlosky, J. C., Mysore, J., Clark, S. P. et al. (2015). Comparison of physiologic and pharmacologic parameters in asian and mauritius cynomolgus macaques. Regul Toxicol Pharmacol 73, 27-42. doi:10.1016/j.yrtph.2015.06.008
Li, X., Li, D., Biddle, K. E. et al. (2022). Age- and sex-related changes in body weights and clinical pathology analytes in cynomolgus monkeys (Macaca fascicularis) of Mauritius origin. Vet Clin Pathol 51, 356-375. doi:10.1111/vcp.13094
Palazzi, X., Anger, L. T., Boulineau, T. et al. (2024). Points to consider regarding the use and implementation of virtual controls in nonclinical general toxicology studies. Regul Toxicol Pharmacol 150, 105632. doi:10.1016/j.yrtph.2024.105632
Riley, J. H. (1992). Clinical pathology: Preanalytical variation in preclinical safety assessment studies--effect on predictive value of analyte tests. Toxicol Pathol 20, 490-500. doi:10.1177/0192623392020003206
Sanz, F., Pognan, F., Steger-Hartmann, T. et al. (2023). Etransafe: Data science to empower translational safety assessment. Nat Rev Drug Discov 22, 605-606. doi:10.1038/d41573-023-00099-5
Siska, W., Schultze, A. E., Ennulat, D. et al. (2022). Scientific and regulatory policy committee points to consider: Integration of clinical pathology data with anatomic pathology data in nonclinical toxicology studies. Toxicol Pathol 50, 808-826. doi:10.1177/01926233221108887
Smith, C. N., Neptun, D. A. and Irons, R. D. (1986). Effect of sampling site and collection method on variations in baseline clinical pathology parameters in Fischer-344 rats. Ii. Clinical hematology. Fundam Appl Toxicol 7, 658-663. doi:10.1016/0272-0590(86)90115-6
Steger-Hartmann, T., Kreuchwig, A., Vaas, L. et al. (2020). Introducing the concept of virtual control groups into preclinical toxicology testing. ALTEX 37, 343-349. doi:10.14573/altex.2001311
Strayhorn, J. M., Jr. (2021). Virtual controls as an alternative to randomized controlled trials for assessing efficacy of interventions. BMC Med Res Methodol 21, 3. doi:10.1186/s12874-020-01191-9
Tripathi, N. K., Everds, N. E., Schultze, A. E. et al. (2017). Deciphering sources of variability in clinical pathology. Toxicol Pathol 45, 90-93. doi:10.1177/0192623316675766
Vap, L. M., Harr, K. E., Arnold, J. E. et al. (2012). ASVCP quality assurance guidelines: Control of preanalytical and analytical factors for hematology for mammalian and nonmammalian species, hemostasis, and crossmatching in veterinary laboratories. Vet Clin Pathol 41, 8-17. doi:10.1111/j.1939-165X.2012.00413.x
Wolford, S. T., Schroer, R. A., Gallo, P. P. et al. (1987). Age-related changes in serum chemistry and hematology values in normal sprague-dawley rats. Fundam Appl Toxicol 8, 80-88. doi:10.1016/0272-0590(87)90102-3